Clinical Trials Logo

Hemostasis clinical trials

View clinical trials related to Hemostasis.

Filter by:

NCT ID: NCT01388491 Completed - Hemostasis Clinical Trials

A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Start date: October 31, 2011
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.

NCT ID: NCT01252186 Completed - Hemostasis Clinical Trials

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.

NCT ID: NCT01060189 Completed - Hemostasis Clinical Trials

Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery

Start date: April 2008
Phase: N/A
Study type: Interventional

Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but expensive, and has been proved to link to higher risks of serious side effects including renal problems, myocardial events, and strokes in patients undergoing CABG. After the secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The objective of the study is to evaluate the hemostatic effect of ulinastatin and tranexamic acid in cardiac surgery.

NCT ID: NCT01060176 Recruiting - Hemostasis Clinical Trials

Three Dose Regimen of Tranexamic Acid in Cardiac Surgery

Start date: February 2010
Phase: N/A
Study type: Interventional

Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The current study includes patients receiving valvular replacement and coronary artery bypass surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions and clinical outcomes are recorded.

NCT ID: NCT01053234 Completed - Type 2 Diabetes Clinical Trials

Different Insulin Regimens and Postprandial Coagulation Activation

Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this study in patients with type 2 diabetes was to investigate the acute effect of postprandial blood glucose levels modified by two different insulin treatment regimens on coagulation activation, inflammation and endothelial cell function. The investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial postprandial effect on coagulation, endothelial dysfunction and inflammation compared with the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.

NCT ID: NCT01008436 Terminated - Hemostasis Clinical Trials

Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.

Start date: January 2010
Phase: N/A
Study type: Interventional

The study enrolles all consecutive patients undergoing cardiac surgery at the European Hospital, Rome. The population undergoes randomization to receive usual surgical hemostasis or added topical application of Omni-stat Celox. The two populations are followed up prospectively as regarding blood loss and need for blood transfusions, as well as adverse events at 30 days after surgery.

NCT ID: NCT00918619 Completed - Hemostasis Clinical Trials

Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection

ESSCALIVER
Start date: January 2010
Phase: Phase 4
Study type: Interventional

This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical centres. The primary objective of this study is to show that the collagen based haemostatic device Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) in achieving haemostasis after hepatic resection.

NCT ID: NCT00837954 Completed - Clinical trials for Peripheral Vascular Diseases

Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis

COBBANA
Start date: February 2009
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to demonstrate that the bleeding time of suture holes after construction of arterial bypass anastomosis is shorter after treatment with Lyostypt® than with Surgicel®

NCT ID: NCT00802633 Terminated - Bladder Cancer Clinical Trials

Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?

Start date: November 2008
Phase: N/A
Study type: Interventional

Evaluate the utility/safety of an FDA-approved tissue sealing device during radical cystectomy as compared to an FDA-approved stapling device.

NCT ID: NCT00658723 Completed - Hemostasis Clinical Trials

The Fibrin Patch Soft Tissue Study

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICELâ„¢ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.